8-K: INmune Bio Reveals Mixed Phase 2 XPro Alzheimer's Trial Results, Citing Subpopulation Benefit

INmune Bio announced additional analyses from its Phase 2 MINDFuL trial of XPro for Alzheimer's disease will be presented at the Alzheimers Association International Conference, revealing consistent benefits in a specific patient subpopulation despite not meeting the primary endpoint in the overall group.

Summary

• INmune Bio will present additional analyses from its Phase 2 MINDFuL trial evaluating XPro at the Alzheimers Association International Conference (AAIC) in Toronto, Canada.
• The presentation, led by Dr. Sharon Cohen, is scheduled for Tuesday, July 29, 2025, between 2:00 and 3:30 PM ET.
• The MINDFuL trial was a double-blind, Phase 2 proof-of-concept study involving 208 participants with early-stage Alzheimer's disease (AD) and at least one biomarker of inflammation (elevated C-reactive protein, erythrocyte sedimentation rate, hemoglobin A1c, or an ApoE4 allele).
• Participants received XPro or placebo in a 2:1 ratio for 24 weeks, with cognitive changes measured via the Early Mild Alzheimers Cognitive Composite (EMACC).
• The primary endpoint was not met in the overall modified-intent-to-treat (mITT) group.
• Key changes in clinical measures of cognition, behavior, and AD-related biomarkers demonstrated a consistent benefit of XPro treatment after 6 months in a subpopulation of patients with biomarker-confirmed amyloid-beta (Aβ) pathology and two blood biomarkers of systemic inflammation.

Sentiment

Score: 6

Explanation: While the primary endpoint was not met, the identification of a responsive subpopulation is a significant positive for a Phase 2 proof-of-concept study in a challenging disease like Alzheimer's. This provides a clear path forward for future development and potential strategic partnerships, mitigating the negative impact of the missed primary endpoint.

Positives

• Consistent benefit of XPro treatment observed after 6 months in a subpopulation of patients with biomarker-confirmed amyloid-beta (Aβ) pathology and two blood biomarkers of systemic inflammation.
• Key changes in clinical measures of cognition, behavior, and AD-related biomarkers demonstrated benefit in the specific subpopulation.
• Management is encouraged by the promising findings, highlighting XPro's potential to address neuroinflammation in Alzheimer's disease.
• Targeting inflammation through XPro offers a novel and exciting therapeutic approach that could enhance outcomes for individuals with Alzheimer's.
• Potential for XPro to be used alone or in combination with other treatments.

Negatives

• The primary endpoint of the MINDFuL trial was not met in the overall modified-intent-to-treat (mITT) group.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• No assurance that product candidates will be approved by the US Food and Drug Administration (FDA) or any regulatory body.
• Risks and uncertainties relating to the Company's ability to produce more drug for clinical trials.
• Availability of substantial additional funding for the Company to continue operations and conduct research and development, clinical studies, and future product commercialization.
• Risks related to the Company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Future Outlook

INmune Bio anticipates submitting a publication of the MINDFuL Phase 2 study results by mid-August. The company is also seeking a strategic partnership to accelerate the further development of XPro as a treatment for Alzheimer's disease.

Management Comments

• "We are encouraged by the promising findings of the MINDFuL trial, which highlight the potential of XPro to address neuroinflammation in Alzheimers disease." Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio.
• "These meaningful results reinforce our commitment to developing this therapy that could significantly impact patients and their families." Dr. CJ Barnum.
• "Im pleased to share more of this eagerly anticipated data with the Alzheimers community." Dr. Sharon Cohen, site principal investigator of the MINDFuL trial and medical director of the Toronto Memory Program.
• "Targeting inflammation through XPro offers a novel and exciting therapeutic approach that could enhance outcomes for individuals with Alzheimers, whether used alone or in combination with other treatments." Dr. Sharon Cohen.

Industry Context

The announcement relates to the ongoing global effort to find effective treatments for Alzheimer's disease, a condition with significant unmet medical needs. XPro's focus on neuroinflammation represents a distinct approach compared to amyloid-targeting therapies, which have seen mixed success. The identification of a responsive subpopulation aligns with the growing trend towards precision medicine in complex diseases like AD.

Stakeholder Impact

• Shareholders: Potential for increased value if XPro's development progresses successfully, but also risk due to missed primary endpoint and explicit mention of needing future funding/partnerships.
• Patients/Caregivers: Hope for a novel therapeutic approach to Alzheimer's disease, particularly for those with specific inflammatory biomarkers.
• Employees: Continued employment and potential for growth if the drug advances.
• Partners/Vendors: Potential for future collaboration and business opportunities if strategic partnerships are formed.

Next Steps

• Oral presentation of additional analyses at the Alzheimers Association International Conference (AAIC) on July 29, 2025.
• Anticipated submission of a publication of the MINDFuL Phase 2 study results by mid-August.
• Seeking a strategic partnership to accelerate the further development of XPro as a treatment for Alzheimer's disease.

Key Dates

Recommendation

The mixed results from the Phase 2 MINDFuL trial present a nuanced picture. While the primary endpoint was not met in the overall population, the consistent benefit observed in a specific subpopulation with biomarker-confirmed amyloid-beta pathology and systemic inflammation is a significant positive for a proof-of-concept study in Alzheimer's disease. This suggests a potential path forward for XPro as a precision medicine. However, the need for further development, potential strategic partnerships, and the inherent risks of clinical trials, coupled with the explicit mention of needing "substantial additional funding," warrant a cautious approach. Investors should hold to observe the outcome of the upcoming presentation, the anticipated publication, and any developments regarding strategic partnerships, which could provide clearer direction on the drug's future and the company's financial stability.

Keywords

Alzheimer's disease, neuroinflammation, XPro, MINDFuL trial, Phase 2, clinical trial, biotechnology, soluble TNF inhibitor, INmune Bio, cognitive decline, amyloid-beta, biomarker, AAIC